Fosun Kite
Robin Shang has a diverse work experience that spans over two decades. Starting in 1999, they worked as a Marketing Executive and Salesperson for NuoHua. In 2007, they became a Project Manager at Baxter International Inc., where they excelled in product management and won awards for their marketing plan. In 2011, they joined Sanofi as a Senior Brand Manager, responsible for brand strategy and budget management. From 2013 to 2017, they held various roles at Meiguoyi, including Senior Product Manager and Marketing Manager, where they developed strategic marketing plans and led annual strategy reviews. From 2017 to 2019, they served as a Marketing Manager at Sanofi-Aventis. Most recently, in 2019, they became a Senior Marketing Manager at AstraZeneca. In 2020, they transitioned to Fosun Kite as an Associate Director of Strategic Platform.
Robin Shang earned a Master of Business Administration (M.B.A.) degree in Industrial Management from Shanghai Jiao Tong University from 2009 to 2012. Prior to that, Robin completed a Bachelor's Degree in Business, Management, Marketing, and Related Support Services from China Pharmaceutical University from 1994 to 1998.
This person is not in any teams
Fosun Kite
About Fosun Kite Biotechnology Co., Ltd. As a joint venture of Shanghai Fosun Pharmaceutical (Group) Co., Ltd and U.S. Kite Pharma, Fosun Kite Biotechnology Co., Ltd. (hereinafter referred as "Fosun Kite") was established in April 2017 in Shanghai China. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients. In early 2017, Fosun Kite brought in the world’s first approved CAR-T therapy for NHL Axicabtagene ciloleucel (US trade name Yescarta) from Kite Pharma (project name FKC876). Having obtained the comprehensive technology transfer and commercial license, the company has built a class B+A clean cell preparation base which is up to the latest GMP standards and in line with Kite’s commercial production standards and plant design concept. In August 2018, FKC876 officially obtained the Investigational New Drug (IND) approval from China National Medical Products Administration (NMPA), and now is carrying out registrational clinical trials strictly following GCP and other regulatory requirements in China to provide evidence in support of its successful registration. In January 2019, a commercial manufacture base of approx.10,000sqm settled in South Zhangjiang for commercial production of CAR-T therapies including FKC876 following registration. Besides Yescarta, Fosun Kite also collaborates with leading immunotherapy R&D organizations at home and abroad to build a rich and independent R&D pipeline.